Steve Martin

Dec 16, 2014

Applied Proteomics has appointed Steve Martin as CFO.

Martin was previously CFO of pharma firm Apricus Biosciences. Before that he was CFO and interim CEO of BakBone Software. He was also CFO of Strategene, which was sold to Agilent in 2007, and controller for Gen-Probe, now a part of Hologic.

More Like This

Nov 16, 2017

Emma Millican, Harold Swerdlow

LGC has appointed Emma Millican as global NGS business unit manager and Harold Swerdlow as head of NGS technology development, positions the firm created to support the launch of its new NGS business unit. 

Millican was previously director of scientific operations at the Wellcome Trust Sanger Institute and prior to joining the Sanger Institute, she was the UK director of forensic and applied genetics at Eurofins.

Swerdlow joins LGC from the New York Genome Center, where he was vice president of sequencing. Previously, he was head of research and development at the Wellcome Trust Sanger Institute and also served as chief technology officer at the Dolomite Center.

Nov 15, 2017

Mitch Levine

OncoCyte said that Mitch Levine has been appointed chief financial officer. Prior to joining OncoCyte, Levine was managing partner of Kirby Cover Capital Advisors, which provides consulting to international life sciences investment funds regarding US-based companies. In 2002 Levine founded Enable Capital Management. Prior to that, he was a founding member of The Shemano Group. He has also worked for Bear Stearns and Lehman Brothers.

Nov 14, 2017

Huntington Willard

Geisinger Health System has named Huntington Willard as director of the newly launched Geisinger National Precision Health Initiative, to be based near Washington, DC. Among his duties, Willard will oversee formation of a new precision health innovation lab. Willard, who was founding director of the Duke Institute for Genome Sciences & Policy and is a former president of the American Society of Human Genetics, will start in January. 

Nov 14, 2017

Samuel Riccitelli, David Cohen

Precipio has appointed Samuel Riccitelli as chairman, replacing Robert Patzig who resigned after seven years on the board of Transgenomic, which recently merged with Precipio. Also, David Cohen was elected as a new director at Precipio to fill an existing vacancy. 

Riccitelli has been on Precipio's board since June. From October 2012 through February 2017, he was president and CEO of Signal Genetics, where he also was a director. Before that, he was executive vice president and COO of Genoptix.

Cohen is COO and co-owner of Standard Oil of Connecticut, and has founded several ventures, including My Gene Counsel, a cancer bioinformatics company.

Nov 13, 2017

Chris Connelly, Brad Hunsley, Carissa Moore, Subodh Nimkar, John Scholl

Streck announced five new members of its leadership team: 

  • Chris Connelly, director of R&D for new product development/molecular. Connelly joined Streck in 2010 and was previously R&D scientific manager for the molecular division. 
  • Brad Hunsley, director of R&D for application development/existing products. Hunsley joined Streck in 1989, has held various leadership positions, and is currently a member of the company's scientific advisory committee.
  • Carissa Moore, director of R&D for new product development/stabilization and flow cytometry. Moore joined Streck in 2011 as an R&D scientist, and she served as R&D scientific manager from 2016 to 2017.
  • Subodh Nimkar, director of strategic marketing. Nimkar most recently served as a North America marketing programs manager at Agilent Technologies.
  • John Scholl, director of R&D for application development/private label products. Scholl joined Streck's R&D department in 1987 as a technician and was promoted to various supervisory positions in the department.
Nov 13, 2017

Annalisa Jenkins

PlaqueTec has appointed Annalisa Jenkins its CEO. She will lead the company's launch in 2018 of its biomarker-based PlaqueTec Liquid Biopsy System, which is being developed to improve risk assessment and enable earlier intervention in the management of coronary artery disease. The system collects biomarkers directly associated with plaques whtin coronary arteries in order to assess residual inflammatory risk. Jenkins formerly was the CEO of Dimension Therapeutics. Prior to that, she was Executive Vice President, Head of Global R&D for Merck Serono.

Nov 13, 2017

Eric Johnson, Ashley Kiley

Tenet Diagnostics has appointed Eric Johnson as director of laboratory services and Ashley Kiley as director of provider relations. Johnson is joining Tenet from Advanced Clinical Laboratory Solutions (ACLS), where he serves as laboratory director. He has also been a laboratory director at Iverson Genetics and Parabase Genomics. Kiley will also join Tenet from ACLS, where she serves as sales director. She has also served as a marketing manager for Pain Physicians NY.

Nov 10, 2017

John Gu

WuXi NextCode has hired John Gu as chief digital officer. A former CIO of Chinese internet service provider and search engine Baidu, Gu comes to the genomic data firm from consulting firm Silver Sand Technologies. At WuXi NextCode, the US-educated Gu will lead expansion of the company's data platform in China.

Nov 09, 2017

Doug Liu, Mark Gladwell, Laura Furmanski

Doug Liu is retiring from his role as senior vice president of global operations at Qiagen, CEO Peer Schatz said during an earnings call this week. He will be succeeded by Mark Gladwell, who joined the company from Alere, where he most recently served as senior vice president of global operations. 

In addition, Schatz said that Laura Furmanski, senior vice president of the bioinformatics business area, has resigned from the company. A search for her successor is in an advanced stage, Schatz said.

Nov 08, 2017

Nicholas Potter

Nicholas Potter joined Epigenomics as director of reimbursement and medical affairs, effective Nov. 1. In his position, he will create the firm's reimbursement strategy for its blood-based menu of methylated cancer detection technologies. Most recently, Potter was at MPLN as laboratory director of molecular diagnostics, CSO, and finally executive vice president of clinical affairs. 

Nov 08, 2017

Gary Guthart

Illumina has named Gary Guthart to its board of directors, effective Dec. 1, 2017. Guthart is president and CEO of Intuitive Surgical, which makes robots to assist with minimally invasive surgery. He has held a variety of roles at Intuitive Surgical since 1996 and previously developed foundational technology for computer-enhanced surgery at SRI International, which was formerly the Stanford Research Institute. He also served on the board of directors at Affymetrix from 2009 until it was acquired by Thermo Fisher Scientific in 2016.

Nov 07, 2017

Harold Rabinovitz

Dermtech announced today that it has appointed Harold Rabinovitz to its scientific advisory board. Rabinovitz currently serves as a volunatary clinical professor of dermatology at the University of Miami School of Medicine. 

Nov 06, 2017

Lily Sarafan

Home Care Assistance CEO Lily Sarafan has joined the board of Counsyl. She also serves on the boards of AI company Entefy, the Stanford Alumni Association, and the Berkeley Haas Center for Innovation Economies. 

Nov 06, 2017

Jorge Garces

Epigenomics has appointed Jorge Garces as president and CSO, effective Dec. 1. He will join the firm's executive board and oversee operations, R&D, clinical affairs, regulatory and quality. Prior to joining Epigenomics, Garces was CEO and president of AltheaDx. Before that, he held the same positions at Enigma Diagnostics. He also has held management positions at Hologic and GenMark Diagnostics, as well as Third Wave Technologies. 

Nov 03, 2017

Kathy Ordoñez

Pacific Biosciences has hired Kathy Ordoñez as chief commercial officer. Ordoñez has been a member of PacBio's board of directors since 2014 and will continue in that role, as well. Ordoñez was most recently CEO of RainDance Technologies. She was also previously senior vice president at Quest Diagnostics where she led the company's R&D efforts and provided oversight to businesses commercializing diagnostic products and testing services. She served as CEO at Celera and was a founder of Celera Diagnostics before the company was acquireid by Quest Diagnostics. She also held several positions at Hoffmann-La Roche, including overseeing the formation of Roche Molecular Systems.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.